全文获取类型
收费全文 | 53514篇 |
免费 | 3890篇 |
国内免费 | 963篇 |
专业分类
耳鼻咽喉 | 313篇 |
儿科学 | 2495篇 |
妇产科学 | 3285篇 |
基础医学 | 4450篇 |
口腔科学 | 627篇 |
临床医学 | 5485篇 |
内科学 | 13606篇 |
皮肤病学 | 850篇 |
神经病学 | 3597篇 |
特种医学 | 1241篇 |
外国民族医学 | 1篇 |
外科学 | 5816篇 |
综合类 | 3809篇 |
现状与发展 | 3篇 |
一般理论 | 13篇 |
预防医学 | 4626篇 |
眼科学 | 1719篇 |
药学 | 2472篇 |
5篇 | |
中国医学 | 577篇 |
肿瘤学 | 3377篇 |
出版年
2024年 | 85篇 |
2023年 | 618篇 |
2022年 | 467篇 |
2021年 | 788篇 |
2020年 | 711篇 |
2019年 | 372篇 |
2018年 | 1128篇 |
2017年 | 1082篇 |
2016年 | 1250篇 |
2015年 | 1203篇 |
2014年 | 1173篇 |
2013年 | 1615篇 |
2012年 | 3215篇 |
2011年 | 3895篇 |
2010年 | 1801篇 |
2009年 | 1639篇 |
2008年 | 3472篇 |
2007年 | 3397篇 |
2006年 | 3038篇 |
2005年 | 3298篇 |
2004年 | 4105篇 |
2003年 | 4024篇 |
2002年 | 3106篇 |
2001年 | 2413篇 |
2000年 | 934篇 |
1999年 | 953篇 |
1998年 | 953篇 |
1997年 | 799篇 |
1996年 | 582篇 |
1995年 | 416篇 |
1994年 | 480篇 |
1993年 | 478篇 |
1992年 | 531篇 |
1991年 | 477篇 |
1990年 | 432篇 |
1989年 | 394篇 |
1988年 | 324篇 |
1987年 | 307篇 |
1986年 | 281篇 |
1985年 | 200篇 |
1984年 | 146篇 |
1983年 | 140篇 |
1982年 | 127篇 |
1981年 | 127篇 |
1980年 | 114篇 |
1979年 | 99篇 |
1978年 | 85篇 |
1977年 | 84篇 |
1975年 | 97篇 |
1973年 | 91篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers 下载免费PDF全文
2.
3.
Increased arterial stiffness in young normotensive patients with Turner syndrome: associations with vascular biomarkers 下载免费PDF全文
4.
5.
6.
María Cabrerizo Gloria Trallero María José Pena Amaia Cilla Gregoria Megias Carmen Mu?oz-Almagro Eva Del Amo Diana Roda Ana Isabel Mensalvas Antonio Moreno-Docón Juan García-Costa Nuria Rabella Manuel Ome?aca María Pilar Romero Sara Sanbonmatsu-Gámez Mercedes Pérez-Ruiz María José Santos-Mu?oz Cristina Calvo And the study group of “Enterovirus parechovirus infections in children under ?years-old Spain” PI- 《European journal of pediatrics》2015,174(11):1511-1516
7.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C 下载免费PDF全文
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316
8.
GIUSEPPE BORIANI MAURO BIFFI MAURIZIO RUSSO† MAURIZIO LUNATI‡ GIANLUCA BOTTO¶ ALESSANDRO PROCLEMER§ GIUSEPPE VERGARA WERNER RAHUE†† CRISTIAN MARTIGNANI RENATO RICCI† MASSIMO SANTINI† On Behalf of the SEARCH MI Registry Italian Investigators 《Pacing and clinical electrophysiology : PACE》2006,29(S2):S29-S34
Background: Large randomized trials show that in appropriately selected patients with left ventricular dysfunction, implantable cardioverter-defibrillators (ICDs) can improve overall survival at 2–5 years. Since direct implementation of the criteria used in the MADIT II and SCD-HeFT will lead to a marked rise in ICD implants, there is a growing fear that increased use of ICDs may cause a dramatic burden to health care systems. The ICD has traditionally been seen as an expensive form of treatment, which is difficult to accept at the first look. This is mainly due to the nonlinear character of the ICD investment, characterized by high initial expenditure, followed by a deferred pay-off in terms of clinical benefits. Cost-effectiveness analysis may help provide a different perspective on the problem of ICD cost, as may estimation of the daily cost of ICD treatment, assuming a time horizon of 5–7 years—a particularly interesting subject for further registry studies.
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
9.
10.
F Boomsma F A van der Hoorn A J Man in 't Veld M A Schalekamp 《Clinica chimica acta; international journal of clinical chemistry》1988,178(1):59-69
We report a reliable method for determining DOPA levels in plasma and cerebrospinal fluid. The method is based on complete conversion of DOPA to dopamine and quantification by HPLC-ECD of the dopamine formed. Lower limit of detection was 0.5 nmol/l. No differences in plasma DOPA levels were found between normal children (0-15 yr, n = 60), normal adults (n = 39) and patients with essential hypertension (n = 40) or Parkinson's disease (no DOPA therapy, n = 30). In normal individuals and in patients with essential hypertension venous plasma levels were higher than arterial levels (10.2 vs 9.3 nmol/l, p less than 0.001, V/A ratio 1.11 (SD 0.08), n = 15). Sympathetic stimuli (standing, tilting, bicycle exercise, tyramine) did not influence DOPA levels. In untreated depressed patients (n = 10) and in non-parkinsonian neurological patients (n = 12) cerebrospinal fluid levels of DOPA were 4.5 (SD 2.4) and 5.2 (SD 1.3) nmol/l respectively. A direct method for the measurement of DOPA by HPLC-ECD after deproteinization of plasma is also described and compared with the conversion method. Good agreement was found when plasma DOPA levels exceeded 0.25 mumol/l (y(conversion method) = 0.943x (direct method) + 0.118; n = 60; r = 0.985). The direct method, because of greater simplicity and the possibility of simultaneous measurement of the DOPA metabolite 3-O-methyldopa, is the method of choice with plasma samples from DOPA-treated patients. In non-DOPA treated individuals the conversion method is superior and has proved to be an accurate and sensitive method for the determination of DOPA levels in plasma and cerebrospinal fluid. 相似文献